Iterum Therapeutics Announces Completion Of Enrollment In Its REASSURE Phase 3 Clinical Trial Of Oral Sulopenem In Uncomplicated Urinary Tract Infections
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics has completed enrollment in its REASSURE Phase 3 clinical trial of oral Sulopenem for uncomplicated urinary tract infections.
October 24, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iterum Therapeutics' completion of enrollment for its Phase 3 clinical trial could potentially accelerate the drug's approval process, positively impacting the company's stock.
The completion of enrollment for a Phase 3 clinical trial is a significant milestone in the drug development process. This could potentially accelerate the approval process for the drug, which would be a positive development for the company and could positively impact the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100